What type of study is this?

This is a Cohort Study study (also classified as: Animal Study).

September 22, 2025Cell Reports MedicineOpen Access

FLT3L-based drug conjugate effectively targets chemoresistant leukemia stem cells in acute myeloid leukemia

View Full Paper

Ask AI

Bookmark

Authors

This research demonstrates FL-Fc-DM1 effectively reduces leukemia stem cell frequency in AML, suggesting a new therapeutic option.

FL-Fc-DM1 showcases potent anti-leukemic activity in multiple models, significantly impacting chemoresistant cells.
The drug conjugate notably promotes apoptosis and cell cycle entry in cytarabine-resistant AML cells, enhancing treatment efficacy.
Toxicity assessments reveal minimal effects on normal human hematopoiesis at therapeutic doses, supporting potential as a safe option.
Combining FL-Fc-DM1 with BH3 mimetics can further improve therapeutic outcomes for patients with AML.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark